GIPZIDE TABLET 5MG

Nazione: Malesia

Lingua: inglese

Fonte: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Principio attivo:

GLIPIZIDE

Commercializzato da:

IMEKS PHARMA SDN. BHD.

INN (Nome Internazionale):

GLIPIZIDE

Confezione:

100 Tablets; 500 Tablets

Prodotto da:

Sriprasit Pharma Co. Ltd.

Foglio illustrativo

_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP)_
GIPZIDE TABLET
Glipizide (5mg)
_ _
1
WHAT IS IN THIS LEAFLET
1.
What GIPZIDE is used for
2.
How GIPZIDE works
3.
Before you use GIPZIDE
4.
How to use GIPZIDE
5.
While you are using it
6.
Side effects
7.
Storage and Disposal of GIPZIDE
8.
Product Description
9.
Manufacturer and Product Registration
Holder
10.
Date of Revision
WHAT GIPZIDE IS USED FOR
GIPZIDE
is
used
in
addition
to
diet
and
exercise
to
control
blood
sugar
level
in
people with type 2 diabetes mellitus.
HOW GIPZIDE WORKS
GIPZIDE belongs to a group of medicines
called sulphonylureas, containing the active
ingredient glipizide. GIPZIDE helps to lower
blood sugar level by stimulating the release
of insulin from your pancreas.
BEFORE YOU USE GIPZIDE_ _
-
_When you must not use it_
Do not take GIPZIDE if you have/are:
• allergic to glipizide, other sulphonylureas
or sulphonamides, or any other ingredients of
this medicine (listed in Product Description).
•
insulin-dependent
(type
1)
diabetes
mellitus.
• diabetes ketoacidosis with or without loss
of consciousness.
• severe problems with your kidneys or liver.
• taking miconazole
(antifungal medication).
_ _
_Pregnancy and lactation _
Please consult your doctor or pharmacist if
you are pregnant, planning for pregnancy or
breastfeeding before using any medicine.
Do not take GIPZIDE if you are pregnant, as
it may potentially cause harm to your baby.
If you could get pregnant while receiving
GIPZIDE, a reliable form of contraception
should always be used.
It
is
unknown
whether
GIPZIDE
secreted
into the breast milk or not, however, due to
the
risk
of
side
effects
in
the
baby,
breastfeeding
is
not
recommended
while
taking GIPZIDE.
_ _
_ _
-
_Before you start to use it _
Please consult your doctor or pharmacist if
you have/are:
•
glucose-6-phosphate
dehydrogenase
(G6PD)
enzyme
deficiency
(disorder
that
may cause abnormal destruction of red blood
cells).
• kidney or liver impairment.
•
high
risk
of
getting
low
blood
sugar
(elderly, weak body or not

Scheda tecnica

CONTENT
Each tablet contains Glipizide 5 mg.
DESCRIPTION
White round tablet with a bisect and embossed with “SPS”,
“G06” on one side,
plain on the other.
PHARMACODYNAMICS
Glipizide
is
an
oral
blood-glucose
lowering
agent
of
the
second-generation
sulphonylureas
group.
When
administered
orally,
glipizide
stimulates
insulin
secretion from the beta cells of pancreatic islet tissue. As such, its
action is
dependent on the functioning of the beta cells in pancreatic islet
tissue, which
produce endogenous insulin. Stimulation of insulin secretion by
glipizide is most
pronounced in response to a meal. Long-term administration of
glipizide does not
affect the fasting insulin level, however, it enhances the
postprandial insulin
response following 6 months of treatment. The insulinotropic response
to a meal
occurs within 30 minutes after an oral dose of
Gipzide in diabetic patients, but
elevated insulin levels do not persist beyond the time of the meal
challenge. Blood
sugar control persists in some patients for up to 24 hours after a
single dose of
Gipzide, even though plasma levels have declined to a small fraction
of peak levels
by that time.
PHARMACOKINETICS
Glipizide is rapidly and completely absorbed after oral
administration. Peak plasma
concentration occurs 1 – 3 hours after a single oral dose. The
elimination half-life
for both oral administration and intravenous administration ranges
from 2 – 4
hours
in
healthy
subjects.
First-pass
metabolism
effect
for
glipizide
is
not
significant. When administered with meals, the absorption of glipizide
is delayed
by about 40 minutes, however, the total absorption and disposition of
an oral dose
is not affected. Glipizide is 98 – 99% bound to plasma protein, one
hour after oral
or intravenous administration. Metabolism of glipizide occurs mainly
in the liver.
The primary metabolites which are the inactive hydroxylation products
and the
polar conjugates are excreted mainly in the urine and less than 10% of
glipizide is
excreted unchanged.
INDICATIONS
Glipizide is i